DELFI Diagnostics develops advanced blood-based tests aimed at enhancing cancer detection and early intervention. Utilizing cutting-edge machine learning techniques on whole genome sequencing data, their DELFI platform focuses on analyzing cell-free DNA fragments, which reveal important information about cancerous conditions. One of their notable innovations is the FirstLook Lung test, which leverages extensive data to accurately identify potential lung cancer cases within routine blood work. DELFI's mission emphasizes broader healthcare access, particularly for historically underserved populations, while committing to rigorous scientific standards and ensuring quality. The company values collaboration, diversity, and shared success, promoting a culture that fosters innovation and collective achievement in the pursuit of lifesaving advancements in diagnostics.